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Abstract
Background:  Antidepressant prescribing has been increasing in England. Studies in other
countries suggest that while this may be associated with reduced suicide rates, it may also be
associated with increased fatal poisoning from antidepressant drugs. We therefore conducted an
ecological study to assess the association between prescription rates for antidepressants and
suicide or fatal antidepressant-related poisoning in England.
Methods: The Office for National Statistics provided information on the number of suicides,
antidepressant-related poisoning deaths and populations for England between 1993 and 2002. The
Department of Health supplied data on prescriptions for all antidepressants dispensed in England.
Associations between prescriptions and deaths were assessed using Spearman's rank correlation
coefficient.
Results: There were 46,747 suicides, 3,987 deaths involving tricyclic antidepressants and 430
involving selective serotonin re-uptake inhibitors and other antidepressants. Increased
antidepressant prescribing was statistically associated with a fall in suicide rates (Spearman's rs = -
0.73, p = 0.02) and fatal poisoning involving tricyclic antidepressants (rs = -0.64, p = 0.05). In
contrast, increased prescribing of selective serotonin re-uptake inhibitors and other
antidepressants was statistically associated with an increase in fatal poisoning involving these drugs
(rs = 0.99, p < 0.001).
Conclusion:  Increased prescribing of antidepressants may indicate improved diagnosis and
treatment of depression in primary care. Our analysis suggests that this was accompanied by lower
suicide rates. A decrease in poisoning deaths involving tricyclic antidepressants may suggest a
change in preference for using serotonin reuptake inhibitors and other antidepressant drugs for
high-risk patients. This may also partially explain the increase in deaths involving these drugs. Due
to the ecological nature of the design, we cannot say conclusively whether reduced suicide rates
are a direct consequence of increased antidepressant prescribing rates. To confirm these
associations, individual level data on prescribing and suicide is needed.
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Background
Around 5000 people take their own lives in England every
year [1]. The Government's White Paper Saving Lives: Our
Healthier Nation sets a target to reduce suicide deaths by
20% by 2010 [2]. One of the most common risk factors
amongst suicide victims is a major depressive episode
(present in about 60–90% of victims) [3]. Treatment of
depressed patients can reduce suicide risk by half [3].
Hence, increased diagnosis and treatment of depression in
primary care is a key element in reducing suicide risk.
Studies in Sweden [4], Denmark [5], Finland [5], Norway
[5] and Australia [6] suggest that increased used of antide-
pressants drugs is related with lower suicide rates. How-
ever, other studies have also reported a positive
association between increased prescribing of antidepres-
sants and higher death rates from antidepressant overdose
in Finland [7], Norway [8], Australia [9] and England
[10]. In contrast, studies in Italy [11], Austria [12] and Ire-
land [13] have not observed increased suicide or fatal anti-
depressant poisoning following increases in
antidepressant prescribing.
In England, prescriptions for antidepressants have been
increasing [14,15]. We conducted an ecological study to
assess trends in prescription rates for antidepressants in




Suicide deaths were defined as deaths where the coroner
has given a verdict of suicide or where an open verdict was
reached in a death from injury or poisoning. This is
because it is thought that most open verdicts are cases
where the harm was self-inflicted but there was insuffi-
cient evidence to prove that the deceased deliberately
intended to kill themselves [16]. Open verdicts account
for about 30% of male and 40% of female suicide deaths
[16]. Suicide deaths were identified using the Interna-
tional Classification of Diseases codes shown in Table 1.
Antidepressant-related deaths
The Office for National Statistics has stored drug-poison-
ing mortality data for England and Wales from 1993
onwards in a dedicated database [17]. The database con-
tains data on cause of death, individual characteristics
(age and sex) as well as textual information from the
death certificate. This textual information has been exam-
ined to identify and code the substances involved in the
death. All drugs mentioned are also coded to British
National Formulary categories where appropriate.
Drug poisoning deaths were defined using the Interna-
tional Classification of Diseases codes shown in Table 2.
Antidepressant-related deaths were defined as any drug
poisoning death where an antidepressant drug was men-
tioned on the death certificate, with or without mentions
of alcohol or other drugs. Antidepressant drugs were fur-
ther classified according to their BNF categories (Table 3).
Prescriptions for antidepressant drugs
The Department of Health supplied data on prescriptions
for all antidepressants dispensed in England between
1993 and 2002. Prescription information is derived from
the Prescription Cost Analysis (PCA) system, which col-
lects data from all prescriptions dispensed in the commu-
nity [18]. This includes community pharmacists,
dispensing doctors and prescriptions submitted by pre-
scribing doctors for items personally administered (i.e.
given by the doctor during a consultation). PCA data also
includes prescriptions written in Wales, Scotland, North-
ern Ireland and the Isle of Man but dispensed in England.
Drugs dispensed in hospital or private prescriptions are
not included.
Analysis
Directly age-standardised rates for suicide and antidepres-
sant-related deaths were calculated using the European
Standard Population. Populations for England between
1993 and 2002 were interim revised estimates published
by ONS in September 2003. Prescription rates were pre-
sented as number of prescriptions per 100 population.
Statistical associations between prescription rates and
directly age-standardised rates for antidepressant-related
poisoning deaths and suicides were assessed using Spear-
man's rank correlation coefficient.
Table 1: ICD-9 and ICD-10 classification for suicides
Description ICD-9 ICD-10
All suicides E950–E959, E980–E989 excluding E988.8 with 
verdict pending
X60–X84, Y10–Y34 excluding Y33.9 with verdict 
pending
Non-drug poisoning suicide As above excluding E950.0–E950.5 and E980.0–
E980.5
As above excluding X60–X64 and Y10–Y14BMC Public Health 2004, 4:63 http://www.biomedcentral.com/1471-2458/4/63
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Results
In England between 1993 and 2002, there were 46,747
suicides. Suicide was twice as common in men as in
women. There were 3,987 deaths involving tricyclic anti-
depressants (TCAs, BNF 4.3.1,) and 430 involving selec-
tive serotonin re-uptake inhibitors and other
antidepressants (SSRIs & others, BNF 4.3.3 & 4.3.4). The
number of antidepressant-related deaths was similar for
men and women. Changes in age-specific rates were simi-
lar across all age groups for suicide and antidepressant-
related deaths.
Between 1993 and 2002, age-standardised mortality rates
for suicide decreased from 98.2 to 84.3 per million popu-
lation (Table 4). Rates for TCA poisoning also decreased
from 8.6 to 5.3 per million while mortality rates for SSRIs
& others increased from 0.2 to 1.8 per million. During the
same period, prescriptions per 100 population for all anti-
depressants increased almost two and a half times from
22.4 to 53.2 per 100 population (Table 4). While there
was a modest increase for TCAs from 17.5 to 19.9 per 100
population, prescriptions for SSRIs and others increased
more than seven-fold from 4.6 to 33.1 per 100
population.
Spearman's rank correlation indicate that rates for all sui-
cides were inversely related to prescribing rates for all anti-
depressants combined, rs = -0.73, p = 0.016 (Table 5).
Mortality rates for non-drug poisoning suicides showed a
strong statistical association with prescription rates for all
antidepressants, rs = -0.89, p = 0.005. Antidepressant-
related poisoning mortality rates were also inversely statis-
tically associated with prescription rates for all antidepres-
sants combined, but the association was much weaker, rs
= -0.45, p = 0.187. As most antidepressant-related poison-
ing deaths were due to TCAs, the relationship between
TCA deaths and prescribing were similar to all antidepres-
sants combined. In contrast, SSRI and other-related
deaths increased and prescriptions for SSRIs & others both
increased during the study period rs = 0.99, p < 0.001.
A previous analysis found that about a third of antidepres-
sant-related deaths also have other drugs or substances
mentioned on the death certificate (26% of deaths involv-
ing TCAs, 72% involving SSRIs and others) [19]. Hence,
death certification data may over-estimate deaths attribut-
able to antidepressant overdose. When we excluded
deaths involving other substances from our analysis, anti-
depressant mortality rates were more closely related with
antidepressant prescribing (TCAs rs = -0.71, p = 0.022,
SSRIs & others rs = 0.94, p < 0.001).
Discussion
Increased prescribing of antidepressants was statistically
associated with reduced suicide mortality rates. TCA-
related poisoning deaths also decreased during the study
period although the evidence for a statistical association
with prescribing rates was weaker. Increased prescribing of
SSRIs and other antidepressants was statistically associ-
ated with increased mortality rates involving SSRI & other-
related poisoning, although the rates were much smaller
than for TCA-related poisoning or suicide. Because our
study uses population level data, we cannot conclude that
these associations are necessarily causal.
Limitations
Although the ONS drug poisoning database is the most
complete record of drug poisoning statistics available,
about 10% of these deaths have no specific information
about drug(s) taken [1]. Inconsistency in the investigation
and recording of drug-poisoning deaths may mean that
not all antidepressant-related deaths are identified [17].
Prescribing Cost Analysis data do not record why the drug
was prescribed and antidepressants are increasingly used
Table 2: ICD-9 and ICD-10 classification for drug poisoning
Description ICD-9 ICD-10
Mental and behavioural disorders due to drug use (excluding alcohol and tobacco) 292, 304 305.2-9 F11–F16, F18–F19
Accidental poisoning by drugs, medicaments and biological substances E850–E858 X40–X44
Intentional self-poisoning by drugs, medicaments and biological substances E950.0–E950.5 X60–X64
Poisoning by drugs, medicaments and biological substances, undetermined intent E980.0–E980.5 Y10–Y14
Assault by drugs, medicaments and biological substances E962.0 X85
Table 3: British National Formulary Categories for 
Antidepressant Drugs
BNF Category Description
4.3.1 Tricyclics and related antidepressants
4.3.2 Monoamine oxidase inhibitors
4.3.3 Selective serotonin re-uptake inhibitors
4.3.4 Other antidepressantsBMC Public Health 2004, 4:63 http://www.biomedcentral.com/1471-2458/4/63
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for conditions other than depression [20]. This may lead
to an over-estimation of their use in the treatment of
depression. Furthermore, prescribing data does not pro-
vide information on the age or sex of the patient. Both of
these variables are likely to be associated with prescribing
and suicide or poisoning, and may have introduced con-
founding into our analysis.
Further bias may have been introduced due to prescriber
and patient factors. Doctors may perceive SSRIs and other
antidepressants to have clinical advantages over TCAs due
to their lower toxicity, possibly making them more popu-
lar for treating newly diagnosed (an uncontrolled) depres-
sion [21], treating individuals who are at a greater risk of
overdose [22] or individuals who have not previously
responded to treatment.
Interpretation
Assessing the impact of increased antidepressant prescrib-
ing is difficult. This is because antidepressants are both a
treatment and method for suicidal behaviour. Suicide is
also closely linked to availability of methods [23], gener-
ating concern that increased prescribing of antidepres-
sants may increase fatal poisoning rates. There has also
been concern that some antidepressants, particularly the
SSRIs, may actually precipitate suicide behaviour [24]. In
a recent article, Jick et al suggested that both older and
newer antidepressants were associated with 3–4 fold
increased risk of suicidal behaviour in the first month
after starting treatment [25]. Hence, determining the bal-
ance of risk and benefit of treatment with antidepressants
is not straightforward. Using a theoretical model based on
paediatric trails of antidepressants drugs and increased
prevalence of suicidal thoughts and self-harm, Gunnell
Table 4: Age-standardised mortality rates for suicide and antidepressant-related poisoning deaths and prescriptions per 100 
population in England
Year Age-standardised mortality rates per million 
population
Prescriptions per 100 population
Suicide TCAs SSRIs All TCAs SSRIs
1993 98.2 8.6 0.2 22.4 17.5 4.6
1994 94.8 8.7 0.1 24.5 17.9 6.2
1995 95.6 8.7 0.4 27.4 18.3 8.7
1996 90.6 9.7 0.4 30.9 18.8 11.8
1997 92.8 9.4 0.6 34.7 19.3 15.1
1998 95.7 8.8 0.7 37.9 19.7 17.9
1999 95.1 8.0 1.1 41.2 19.7 21.2
2000 90.2 6.9 1.3 44.9 19.7 25.0
2001 84.9 5.8 1.8 49.3 19.8 29.3
2002 84.3 5.3 1.8 53.2 19.9 33.1
Note: Directly standardised to the European Standard Population
Table 5: Spearman's rank correlation coefficients and p-values for directly age-standardised suicide and antidepressant poisoning rates 
and prescription rates, England 1993 to 2002
Cause of death Prescriptions rs p
All suicides All antidepressants -0.73 0.016
Non-drug poisoning suicide All antidepressants -0.89 0.005
Antidepressant-related poisoning deaths All antidepressants -0.45 0.187
Tricyclic antidepressant -related poisoning deaths Tricyclic antidepressants -0.64 0.05
Selective serotonin re-uptake inhibitor and other 
antidepressant-related poisoning deaths
Selective serotonin re-uptake inhibitors and other 
antidepressants
0.99 <0.001
Antidepressant only poisoning deaths* All antidepressants -0.53 0.12
Tricylclic antidepressant only poisoning deaths* Tricyclic antidepressants -0.71 0.022
Selective serotonin re-uptake inhibitor and other 
antidepressant only poisoning deaths*
Selective serotonin re-uptake inhibitors and other 
antidepressants
0.94 <0.001
* Where no other drugs were mentioned on the death certificateBMC Public Health 2004, 4:63 http://www.biomedcentral.com/1471-2458/4/63
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and Ashby suggest that compared to 1991, antidepres-
sants may have contributed to an excess of 388 suicides
(95% credibility interval -202 to 704) in 2002 [26].
However, our study indicates that at a population level,
increased antidepressant prescribing in England was sta-
tistically associated with lower rates of suicide and antide-
pressant-related poisoning. One explanation for our
findings is that SSRIs and other antidepressants are being
used in preference to TCAs to treat depression. The per-
ceived side effects of TCAs means they are often prescribed
or taken at sub-therapeutic doses [21,27], leading to poor
management of depression and increased risk of suicide
[28,29]. Furthermore, the lower toxicity profiles of the
newer antidepressants may also lead to preferential use of
SSRIs for high-risk patients, which may in turn explain the
increase in deaths associated with SSRIs and other antide-
pressants. Some support for this is provided by a previous
analysis of antidepressant-related deaths during the same
study period, which showed a decrease in antidepressant-
related deaths per million prescriptions for all TCAs [19].
Nevertheless, the clinical benefits of antidepressant drugs
for the management of depression and prevention of sui-
cide are still unclear. A recent Cochrane review found little
difference between antidepressants and active placebos
on improvement of mood [30]. (Active placebos contain
a drug, which is not thought to have an effect on the dis-
order being treated, but which mimics the effect of taking
an active substance). The possibility that antidepressants
have limited effectiveness on treatment of depression sug-
gests that we should be cautious when drawing conclu-
sions about the relationship between antidepressant
prescribing and suicide. Increased antidepressant pre-
scribing may be a marker of improved diagnosis and treat-
ment of depression in primary care with greater use of
non-pharmacological and psychosocial interventions [6].
Alternatively, suicide rates may reflect other trends during
the study period: unemployment, which is associated
with suicide [31], fell from about 10% to below 5% dur-
ing the study period [32]. In contrast, consumption of
alcohol, mentioned in 28% of antidepressant poisoning
deaths, remained relatively stable [33]. Hence, the ecolog-
ical nature of our data means that we cannot say conclu-
sively whether reduced suicide rates is a direct
consequence of increased antidepressant prescribing
rates.
Conclusions
The public health impact of increased prescribing of anti-
depressants remains unclear, including whether this leads
to lower suicide rates, and whether this could be a marker
for improved diagnosis and treatment of depression in
primary care. Our analysis of data for England between
1993 and 2002 suggest that increased prescribing of anti-
depressants was associated with lower suicide rates and
probably lower rates of poisoning involving TCAs. This
may have been due to a change in preference for SSRIs and
other antidepressants for high-risk patients but also to
other secular trends in areas like unemployment. The
increase in prescribing rates does however probably
explain the increase in fatal poisonings involving SSRIs
and other antidepressants, which are generally considered
to be less toxic than older agents. Further analysis of indi-
vidual level data, possibly from longitudinal general prac-
tice patient data as well as from primary care based clinical
trials, are needed to provide better evidence of the role of
antidepressants in reducing suicide.
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